Nadja C. Fenn
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Development of aGD2-SIRPα Fusion Antibodies Targeting Neuroblastoma and the Innate Immune Checkpoint Receptor CD47.
Journal: Molecular cancer therapeutics
Published: November 26, 2024
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy.
Journal: Cancer immunology, immunotherapy : CII
Published: September 24, 2024
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Journal: Journal of hematology & oncology
Published: March 05, 2021
Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Journal: Frontiers in immunology
Published: September 22, 2020
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Journal: Leukemia
Published: June 17, 2020
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Journal: Oncoimmunology
Published: February 20, 2018
Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody.
Journal: The Analyst
Published: March 10, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026